In a recent interview at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) conference in Chicago, Phillip Kuo, M.D., Ph.D, F.A.C.R., discussed the potential impact of urinary activity with positron emission tomography (PET) radiopharmaceuticals, and new phase 3 study data that found low urinary activity with the use of the flotufolastat F 18 injectable agent in patients with prostate cancer.
Urinary activity, reportedly a common feature of prostate-specific membrane antigen positron emission tomography (PSMA PET) radiopharmaceuticals, can have an adverse impact on imaging interpretation for detection of new or recurrent prostate cancer.
At initial staging, intense urinary activity with PET radiopharmaceuticals can obscure surrounding areas of the bladder, including the prostate, primary prostate lesions below the bladder, small lymph nodes around the bladder and invasion of the primary prostate tumor into surrounding structures such as the seminal vesicles, noted Phillip Kuo, M.D., Ph.D., F.A.C.R., during a recent interview at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) conference in Chicago.
Dr. Kuo also pointed out that high urinary activity can make it more challenging to diagnose recurrence at the vesicourethral anastomosis, the most common site for prostate cancer recurrence.
(Editor’s note: For related content, see “PSMA PET Imaging May Offer Key Prognostic Markers for Prostate Cancer” and “Can an Emerging PSMA/PET Agent Improve Detection of Prostate Cancer Recurrence in Patients with Low PSAs?”)
However, in a recent study looking at phase 3 from the SPOTLIGHT and LIGHTHOUSE trials, Dr. Kuo and colleagues examined the use of the injectable PET imaging agent flotufolastat F 18 (POSLUMA®, Blue Earth Diagnostics) in 712 patients with either newly diagnosed or recurrent prostate cancer. The study findings, presented at the SNMMI conference, demonstrated that for 96 percent of the cohort, it was possible to distinguish between urinary activity and disease uptake.
“In the vast majority of the cases, urinary activity (with flotufolastat F 18) is low enough in the ureters and bladder that we think it will not potentially affect your ability to detect disease in the pelvis,” noted Dr. Kuo, a professor of medical imaging, biomedical engineering, and medicine at the University of Arizona College of Medicine.
For more insights from Dr. Kuo, watch the video below.
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
SNMMI: Botox May Facilitate Relief from Dry Mouth Side Effect of PSMA-Targeted Radiopharmaceuticals
June 25th 2025For patients being treated with radiopharmaceutical agents for metastatic prostate cancer, the combination of botulinum toxin and an anti-nausea patch led to a 30 percent reduction in PSMA uptake in the salivary glands, according to preliminary research findings presented at the SNMMI conference.
SNMMI: Can 18F-Fluciclovine PET/CT Bolster Detection of PCa Recurrence in the Prostate Bed?
June 24th 2025In an ongoing prospective study of patients with biochemical recurrence of PCa and an initial negative PSMA PET/CT, preliminary findings revealed positive 18F-fluciclovine PET/CT scans in over 54 percent of the cohort, according to a recent poster presentation at the SNMMI conference.
Could an Emerging PET Tracer be a Game Changer for Detecting Hepatocellular Carcinoma?
June 23rd 2025In addition to over 90 percent sensitivity in detecting hepatocellular carcinoma (HCC), the glypican-3 (GPC3) targeted PET tracer 68Ga-aGPC3-scFv appeared to be advantageous in identifying HCC tumors smaller than one centimeter, according to pilot study findings presented at the SNMMI conference.
SNMMI: What a New Meta-Analysis Reveals About Radiotracers for PET/CT Detection of PCa
June 22nd 2025While (68Ga)Ga-PSMA-11 offers a pooled sensitivity rate of 92 percent for prostate cancer, (18F)-based radiotracers may offer enhanced lesion detection as well as improved imaging flexibility, according to a meta-analysis presented at the Society for Nuclear Medicine and Molecular Imaging (SNMMI) conference.
SNMMI: Can Multimodal Monitoring Bolster Outcomes with Pluvicto in Treating mCRPC?
June 22nd 2025Multimodal treatment monitoring, including SPECT/CT exams 24 hours after treatment with Lu-177 PSMA-617, may have facilitated significantly shorter therapy durations and reduced side effects in patients with mCRPC, according to a two-year study presented at the Society for Nuclear Medicine and Molecular Imaging (SNMMI) conference.